1
|
Shaldzhyan A, Zabrodskaya Y, Yolshin N, Kudling T, Lozhkov A, Plotnikova M, Ramsay E, Taraskin A, Nekrasov P, Grudinin M, Vasin A. Clean and folded: Production of active, high quality recombinant human interferon-λ1. Process Biochem 2021; 111:32-39. [PMID: 34493923 PMCID: PMC8411590 DOI: 10.1016/j.procbio.2021.08.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 12/09/2022]
Abstract
Type III interferons exhibit antiviral activity against influenza viruses, coronaviruses, rotaviruses, and others. In addition, this type of interferon theoretically has therapeutic advantages, in comparison with type I interferons, due to its ability to activate a narrower group of genes in a relatively small group of target cells. Hence, it can elicit more targeted antiviral or immunomodulatory responses. Obtaining biologically-active interferon lambda (hIFN-λ1) is fraught with difficulties at the stage of expression in soluble form or, in the case of expression in the form of inclusion bodies, at the stage of refolding. In this work, hIFN-λ1 was expressed in the form of inclusion bodies, and a simple, effective refolding method was developed. Efficient and scalable methods for chromatographic purification of recombinant hIFN-λ1 were also developed. High-yield, high-purity product was obtained through optimization of several processes including: recombinant protein expression; metal affinity chromatography; cation exchange chromatography; and an intermediate protein refolding stage. The obtained protein was shown to feature expected specific biological activity in line with published effects: induction of MxA gene expression in A549 cells and antiviral activity against influenza A virus.
Collapse
Affiliation(s)
- Aram Shaldzhyan
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Yana Zabrodskaya
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia.,Petersburg Nuclear Physics Institute named by B. P. Konstantinov of National Research Center "Kurchatov Institute", mkr. Orlova roshcha 1, Gatchina, 188300, Russia
| | - Nikita Yolshin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Tatiana Kudling
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Alexey Lozhkov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| | - Marina Plotnikova
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Edward Ramsay
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Aleksandr Taraskin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| | - Peter Nekrasov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Mikhail Grudinin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Andrey Vasin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| |
Collapse
|
2
|
Komissarov A, Fadeev A, Kosheleva A, Sintsova K, Grudinin M. Development of a realtime RT-PCR assay for the rapid detection of influenza A(H2) viruses. Mol Cell Probes 2017; 35:57-63. [PMID: 28652020 PMCID: PMC7126497 DOI: 10.1016/j.mcp.2017.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 06/21/2017] [Accepted: 06/22/2017] [Indexed: 11/01/2022]
Abstract
Influenza and other acute respiratory infections are of great concern for public health, causing excessive morbidity and mortality throughout the world. Influenza virus A(H2N2), which caused a pandemic of so called "Asian flu" in 1957 was expelled from the human population by the new pandemic virus subtype H3N2 in 1968, however, influenza A(H2) viruses continue to circulate in wild birds and poultry. The lack of immunity in human population and the continued circulation of influenza A(H2) among animals makes emergence of a new pandemic virus possible. One of the basic techniques of molecular diagnostics of infectious diseases is the realtime polymerase chain reaction (PCR). The aim of this work was to design oligonucleotide primers and probes for the rapid detection of influenza A virus subtype H2 by realtime reverse transcription - polymerase chain reaction (rRT-PCR). Analysis of 539 sequences of influenza A(H2N2) virus hemagglutinin gene from GISAID EpiFlu database revealed conservative regions suitable for use as binding sites for primers and probes. 191 probes were designed and 2 sets of primers and probes (H2-1 and H2-2) were selected for further experimental evaluation. Detection limit of RT-PCR system was 50 copies of DNA per 25 μl reaction when 10-fold dilutions of pCI-neo-H2 plasmid used as template. Analytical specificity of selected sets of primers and probes were tested on wide range of influenza strains and non-influenza respiratory viruses. H2-2 set found to have insufficient specificity detecting seasonal influenza A(H1N1) viruses and was excluded from further analysis. Analytical sensitivity was further tested on vaccine strain A/17/California/66/395 (H2N2) and A/Japan/305/1957 (H2N2), limit of detection for primers-probe set H2-1 was 3.2 (CI95%: 3.07-3.48) lg EID50/ml. Designed primers and probes for the realtime RT-PCR universal detection of influenza A(H2) viruses could be used in clinical trials of vaccines against influenza A(H2) and screening for H2 in cases of unsubtypeable influenza A in humans.
Collapse
Affiliation(s)
- Andrey Komissarov
- Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Laboratory of Molecular Virology, Prof. Popova 15/17, Saint Petersburg, 197376, Russia; Saint Petersburg University, Faculty of Biology, Department of Biochemistry, 7/9 Universitetskaya emb., Saint Petersburg, 199034, Russia; ITMO University, Department of Laser Systems and Technologies, Kronverkskiy Ave, 49, Saint Petersburg, 197101, Russia.
| | - Artem Fadeev
- Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Laboratory of Molecular Virology, Prof. Popova 15/17, Saint Petersburg, 197376, Russia
| | - Anna Kosheleva
- Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Laboratory of Molecular Virology, Prof. Popova 15/17, Saint Petersburg, 197376, Russia
| | - Kseniya Sintsova
- Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Laboratory of Molecular Virology, Prof. Popova 15/17, Saint Petersburg, 197376, Russia
| | - Mikhail Grudinin
- Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Laboratory of Molecular Virology, Prof. Popova 15/17, Saint Petersburg, 197376, Russia
| |
Collapse
|
3
|
López-Labrador FX, Natividad-Sancho A, Pisareva M, Komissarov A, Salvatierra K, Fadeev A, Moya A, Grudinin M, Díez-Domingo J, Afanasieva O, Konovalova N, Sominina A, Puig-Barberà J. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. J Clin Virol 2016; 84:32-38. [PMID: 27690141 DOI: 10.1016/j.jcv.2016.09.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 09/06/2016] [Accepted: 09/19/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Continuous surveillance for genetic changes in circulating influenza viruses is needed to guide influenza prevention and control. OBJECTIVES To compare intra-seasonal influenza genetic diversity of hemagglutinin in influenza A strains isolated from influenza hospital admissions collected at two distinct sites during the same season. STUDY DESIGN Comparative phylogenetic analysis of full-length hemagglutinin genes from 77 isolated influenza A viruses from the St. Petersburg, Russian Federation and Valencia, Spain sites of the Global Influenza Hospital Surveillance Network (GIHSN) during the 2013/14 season. RESULTS We found significant variability in A(H3N2) and A(H1N1)pdm09 viruses between the two sites, with nucleotide variation at antigenic positions much lower for A(H1N1)pdm09 than for A(H3N2) viruses. For A(H1N1)pdm09, antigenic sites differed by three to four amino acids from the vaccine strain, two of them common to all tested isolates. For A(H3N2) viruses, antigenic sites differed by six to nine amino acids from the vaccine strain, four of them common to all tested isolates. A fifth amino acid substitution in the antigenic sites of A(H3N2) defined a new clade, 3C.2. For both influenza A subtypes, pairwise amino acid distances between circulating viruses and vaccine strains were significantly higher at antigenic than at non-antigenic sites. Whereas A(H1N1)pdm09 viruses clustered with clade 6B and 94% of A(H3N2) with clade 3C.3, at both study sites A(H3N2) clade 3C.2 viruses emerged towards the end of the season, showing greater pairwise amino acid distances from the vaccine strain compared to the predominant clade 3C.3. CONCLUSIONS Influenza A antigenic variants differed between St. Petersburg and Valencia, and A(H3N2) clade 3C.2 viruses were characterized by more amino acid differences from the vaccine strain, especially at the antigenic sites.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- Child, Preschool
- Epidemiological Monitoring
- Female
- Genetic Variation
- Genome, Viral
- Global Health
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Humans
- Infant
- Influenza A Virus, H1N1 Subtype/genetics
- Influenza A Virus, H1N1 Subtype/isolation & purification
- Influenza A Virus, H3N2 Subtype/genetics
- Influenza A Virus, H3N2 Subtype/isolation & purification
- Influenza, Human/epidemiology
- Influenza, Human/virology
- Male
- Middle Aged
- Phylogeny
- RNA, Viral/genetics
- Russia/epidemiology
- Seasons
- Sequence Analysis, DNA
- Spain/epidemiology
- Young Adult
Collapse
Affiliation(s)
- F Xavier López-Labrador
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain; Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Publica (CIBER-ESP), Instituto de Salud Carlos III, Spain.
| | - Angels Natividad-Sancho
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| | - Maria Pisareva
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Andrey Komissarov
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Karina Salvatierra
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain; Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain.
| | - Artem Fadeev
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Andrés Moya
- Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain.
| | - Mikhail Grudinin
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Javier Díez-Domingo
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| | - Olga Afanasieva
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Nadezhda Konovalova
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Anna Sominina
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| |
Collapse
|
4
|
Komissarov A, Fadeev A, Sergeeva M, Petrov S, Sintsova K, Egorova A, Pisareva M, Buzitskaya Z, Musaeva T, Danilenko D, Konovalova N, Petrova P, Stolyarov K, Smorodintseva E, Burtseva E, Krasnoslobodtsev K, Kirillova E, Karpova L, Eropkin M, Sominina A, Grudinin M. Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation). Influenza Other Respir Viruses 2016; 10:247-53. [PMID: 26992820 PMCID: PMC4910175 DOI: 10.1111/irv.12389] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2016] [Indexed: 12/14/2022] Open
Abstract
A dramatic increase of influenza activity in Russia since week 3 of 2016 significantly differs from previous seasons in terms of the incidence of influenza and acute respiratory infection (ARI) and in number of lethal cases. We performed antigenic analysis of 108 and whole-genome sequencing of 77 influenza A(H1N1)pdm09 viruses from Moscow and Saint Petersburg. Most of the viruses were antigenically related to the vaccine strain. Whole-genome analysis revealed a composition of specific mutations in the internal genes (D2E and M83I in NEP, E125D in NS1, M105T in NP, Q208K in M1, and N204S in PA-X) that probably emerged before the beginning of 2015/2016 epidemic season.
Collapse
Affiliation(s)
- Andrey Komissarov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Artem Fadeev
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Maria Sergeeva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Influenza Vaccines, Saint Petersburg, Russia
| | - Sergey Petrov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Influenza Vaccines, Saint Petersburg, Russia
| | - Kseniya Sintsova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Anna Egorova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Maria Pisareva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Zhanna Buzitskaya
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Tamila Musaeva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, Saint Petersburg, Russia
| | - Daria Danilenko
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Nadezhda Konovalova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Polina Petrova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Kirill Stolyarov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Department of IT, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Elizaveta Smorodintseva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Biotechnology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Elena Burtseva
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Kirill Krasnoslobodtsev
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Elena Kirillova
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Lyudmila Karpova
- Research Institute of Influenza, Laboratory of Influenza and ARI Epidemiology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Mikhail Eropkin
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Anna Sominina
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Biotechnology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Mikhail Grudinin
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| |
Collapse
|
5
|
Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, Grudinin M, Shartukova M, Romanovskaya-Romanko EA, Kudryavets Y, Bezdenezhnykh N, Lykhova O, Semesyuk N, Concetti A, Tsyb A, Filimonova M, Makarchuk V, Yakubovsky R, Chursov A, Shcherbinina V, Shneider A. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget 2014; 4:1829-35. [PMID: 24121124 PMCID: PMC3858567 DOI: 10.18632/oncotarget.1397] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Autophagy plays an important role in neoplastic transformation of cells and in resistance of cancer cells to radio- and chemotherapy. p62 (SQSTM1) is a key component of autophagic machinery which is also involved in signal transduction. Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known. Here we report that the transformation of normal human mammary epithelial cells with diverse oncogenes (RAS, PIK3CA and Her2) causes marked accumulation of p62. Based on this result, we hypothesized that p62 may be a feasible candidate to be an anti-cancer DNA vaccine. Here we performed a preclinical study of a novel DNA vaccine encoding p62. Intramuscularly administered p62-encoding plasmid induced anti-p62 antibodies and exhibited strong antitumor activity in four models of allogeneic mouse tumors - B16 melanoma, Lewis lung carcinoma (LLC), S37 sarcoma, and Ca755 breast carcinoma. In mice challenged with Ca755 cells, p62 treatment had dual effect: inhibited tumor growth in some mice and prolonged life in those mice which developed tumor size similar to control. P62-encoding plasmid has demonstrated its potency both as a preventive and therapeutic vaccine. Importantly, p62 vaccination drastically suppressed metastasis formation: in B16 melanoma where tumor cells where injected intravenously, and in LLC and S37 sarcoma with spontaneous metastasis. Overall, we conclude that a p62-encoding vector(s) constitute(s) a novel, effective broad-spectrum antitumor and anti-metastatic vaccine feasible for further development and clinical trials.
Collapse
Affiliation(s)
- Franco Venanzi
- Laboratory of Translational Biology, Department of Biology MCA, University of Camerino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Stelmakh V, Kozlov V, Komissarov A, Samusenko I, Grudinin M. [Case report of the available of interhenotypic recombinant in chronic hepatitis C: the algorithm of individualization of the antiviral therapy]. Georgian Med News 2013:36-45. [PMID: 23482361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
UNLABELLED In this particular case report (in vivo the persistence of HCV intergenotipic recombinant form /2/1b/ peripheral blood mononuclear cells of patient) is an example of optimizing the standard antiviral therapy (PegIntron + Rebetol). In this paper we report a patient infected by HCV 1b and, probably, recombinant 2/1b that is detected in peripheral blood mononuclear cells (PBMC). CASE DESCRIPTION Patient S., male, 31 years old admitted in January 2009. HCV viral load in serum before treatment 9,630,000 IU/ml. HCV genotyping by sequencing 5'UTR and NS5A. According to phylogenetic analysis NS5A belongs to 1b (sera and PMBC), 5'UTR from serum to 1b, from PBMC to genotype 2. Due to discordant results recombinant 2/1b in PBMC can be suspected. NS5A interferon sensitivity determining region (ISDR) contains mutation R2218H. Laboratory: ALT 71 U/l, AST 62 U/l, GGT 36 U/l. Liver biopsy: HAI 18, fibrosis 3. Immunohistochemically HCV NS3 was detected in lobules and tracts. Elevated CD16 and CD20 was found in lymphoid follicules of portal tracts. Patient received treatment with pegintron (1.5 mg/kg BW) plus ribavirin (1000 mg/day) for 48 weeks. Virological and biochemical response were achieved on 12 wk and remained until the end of treatment and during follow-up. Liver biopsy after treatment: HAI 6, fibrosis II. Immunohistochemically NS3 was still detected in lobules and tracts, CD16 and CD20 decreased in portal tracts. We also discuss the justification of the selected option treatment strategy (reduced time-course of combination antiviral therapy /28 weeks/ and supplementation of course of antiviral therapy without interferon: a combination of interferon inducer /Cycloferon/ or antiviral drugs /Rebetol/ for another 12 weeks.
Collapse
Affiliation(s)
- V Stelmakh
- North-West State Medical University named after I.I. Mechnikov, Department of Internal Medicine and Nephrology, St. Petersburg State University, St. Petersburg, Russia
| | | | | | | | | |
Collapse
|
7
|
Anna S, Burtseva E, Eropkin M, Karpova L, Zarubaev V, Smorodintseva E, Konovalova N, Danilenko D, Prokopetz A, Grudinin M, Pisareva M, Anfimov P, Stolyarov K, Kiselev O, Shevchenko E, Ivanova V, Trushakova S, Breslav N, Lvov D, Klimov A, Moen A, Cox N. INFLUENZA SURVEILLANCE IN RUSSIA BASED ON EPIDEMIOLOGICAL AND LABORATORY DATA FOR THE PERIOD FROM 2005 TO 2012. Am J Infect Dis 2013; 9:77-93. [PMID: 26561480 PMCID: PMC4639464 DOI: 10.3844/ajidsp.2013.77.93] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Exchange of information on and sharing of influenza viruses through the GISRS network has great significance for understanding influenza virus evolution, recognition of a new pandemic virus emergence and for preparing annual WHO recommendations on influenza vaccine strain composition. Influenza surveillance in Russia is based on collaboration of two NICs with 59 Regional Bases. Most epidemiological and laboratory data are entered through the internet into the electronic database at the Research Institute of Influenza (RII), where they are analyzed and then reported to the Ministry of Public Health of Russia. Simultaneously, data are introduced into WHO's Flu Net and Euro Flu, both electronic databases. Annual influenza epidemics of moderate intensity were registered during four pre-pandemic seasons. Children aged 0-2 and 3-6 years were the most affected groups of the population. Influenza registered clinically among hospitalized patients with respiratory infections for the whole epidemic period varied between 1.3 and 5.4% and up but to 18.5-23.0% during the peak of the two pandemic waves caused by influenza A(H1N1) pdm 09 virus and to lesser extent (2.9 to 8.5%) during usual seasonal epidemics. Most epidemics were associated with influenza A(H1N1), A(H3N2) and B co-circulation. During the two pandemic waves (in 2009-2010 and 2010-2011) influenza A(H1N1) pdm 09 predominated. It was accompanied by a rapid growth of influenza morbidity with a significant increase of both hospitalization and mortality. The new pandemic virus displaced the previous seasonal A(H1N1) virus completely. As a rule, most of the influenza viruses circulating in Russia were antigenic ally related to the strains recommended by WHO for vaccine composition for the Northern hemisphere with the exception of two seasons when an unexpected replacement of the influenza B Victoria lineage by Yamagata lineage (2007-2008) and the following return of Victoria lineage viruses (2008-2009) was registered. Influenza surveillance in Russia was improved as a result of enhancing capacity to international standards and the introduction of new methods in NICs such as rRT-PCR diagnosis, regular testing of influenza viruses for susceptibility to antivirals, phylogenetic analysis as well as organization of sentinel surveillance in a number of Regional Base Laboratories. Improvements promoted rapid recognition of the appearance a new pandemic virus in the country and enhancement of confirmation tests in investigation of influenza related death cases.
Collapse
Affiliation(s)
- Sominina Anna
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Elena Burtseva
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Mikhail Eropkin
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Ludmila Karpova
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Vladimir Zarubaev
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | | | - Nadezhda Konovalova
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Daria Danilenko
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Alexandra Prokopetz
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Mikhail Grudinin
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Maria Pisareva
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Pavel Anfimov
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Kirill Stolyarov
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Oleg Kiselev
- WHO National Influenza Centre, Research Institute of Influenza, St.-Petersburg, Russia
| | - Elena Shevchenko
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Valeriya Ivanova
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Svetlana Trushakova
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Nataliya Breslav
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Dmitriy Lvov
- WHO National Influenza Centre, D.I Ivanovsky Institute of Virology, Moscow, Russia
| | - Alexander Klimov
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA
| | - Ann Moen
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA
| | - Nancy Cox
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, USA
| |
Collapse
|
8
|
Komissarov A, Golovina E, Stelmakh V, Samusenko I, Grudinin M. PP-145 Discordant results of HCV genotyping in peripheral blood mononuclear cells from patient with chronic hepatitis C: case report. Int J Infect Dis 2010. [DOI: 10.1016/s1201-9712(10)60213-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Elpaeva E, Poretskova E, Komissarov A, Pisareva M, Grudinin M, Esaulenko E, Kiselov O. PP-104 Chronic hepatitis B: molecular, epidemiological and clinical features in northwest and central Russia. Int J Infect Dis 2009. [DOI: 10.1016/s1201-9712(09)60498-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Wahlgren J, Waldenström J, Sahlin S, Haemig PD, Fouchier RAM, Osterhaus ADME, Pinhassi J, Bonnedahl J, Pisareva M, Grudinin M, Kiselev O, Hernandez J, Falk KI, Lundkvist A, Olsen B. Gene segment reassortment between American and Asian lineages of avian influenza virus from waterfowl in the Beringia area. Vector Borne Zoonotic Dis 2009; 8:783-90. [PMID: 18637721 DOI: 10.1089/vbz.2007.0274] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Since prehistoric times, the Bering Strait area (Beringia) has served as an avenue of dispersal between the Old and the New Worlds. On a field expedition to this area, we collected fecal samples from dabbling ducks, geese, shorebirds, and gulls on the Chukchi Peninsula, Siberia, and Pt. Barrow, Alaska, and characterized the subtypes of avian influenza virus present in them. Four of 202 samples (2%) from Alaska were positive for influenza A virus RNA in two independent polymerase chain reaction (PCR)-based screening assays, while all shorebird samples from the Chukchi Peninsula were negative. Subtypes H3N8 and H6N1 were recorded once, while subtype H8N4 was found in two samples. Full-length sequences were obtained from the three unique isolates, and phylogenetic analysis with representative sequences for the Eurasian and North American lineages of influenza A virus showed that one HA gene clustered with the Eurasian rather than the North American lineage. However, the closest relative to this sequence was a North American isolate from Delaware described in 2002, indicating that a H6 spillover from Asia has established itself in North America.
Collapse
Affiliation(s)
- J Wahlgren
- Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden., Swedish Institute for Infectious Disease Control, Solna, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|